Current and forthcoming pharmacotherapies for adolescent obesity: Evidence-based review
World Journal of Clinical Pediatrics · 09.09.2026 · 15 (3)
DOI: 10.5409/wjcp.118730 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift World Journal of Clinical Pediatrics, online erschienen am 09.09.2026. Verfasst von Jenyfer M Fuentes-Mendoza und 9 weiteren Autor:innen. Beteiligte Einrichtung: Grupo de Investigación en Neurociencias, Metabolismo, Efectividad Clínica y Sanitaria, Universidad Científica del Sur, Lima 15067, Peru. Die Arbeit nennt 82 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
The prevalence of adolescent obesity has increased substantially in recent decades. This disease affects more than 20% of young people. Obesity is associated with metabolic disorders and heart disease. Conservative treatments are not effective in severe obesity. Therefore, this minireview aims to compare and clarify the effectiveness of treatments. It also seeks to identify areas requiring attention to guide clinical practice and future research. A literature search was conducted in databases including PubMed and Scopus. The study focused on randomised trials and meta-analyses in patients aged 12 to 18 years and lasting more than 12 weeks. The results show an improvement induced by glucagon-like peptide 1 receptor agonists, such as semaglutide. Semaglutide reduces body mass index by 16.1%. It is more effective than liraglutide in improving insulin sensitivity. The use of these drugs faces challenges, such as cost. There are also social inequalities that affect health equity. Although no short-term safety issues have been reported, there is still little information available on Tirzepatide and CagriSema in adolescents, compared to their known effect on adults. Therefore, we conclude that semaglutide is the current gold standard, but that there is an urgent need for longer-term studies, comparative evaluations, and safety trials that include paediatric cohorts in order to ensure safe access to pharmacological innovations.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Grupo de Investigación en Neurociencias, Metabolismo, Efectividad Clínica y Sanitaria, Universidad Científica del Sur, Lima 15067, Peru.
- Grupo de Investigación en Neurociencias, Metabolismo, Efectividad Clínica y Sanitaria, Universidad Científica del Sur, Lima 15067, Peru. mconcepcion@cientifica.edu.pe.
- School of Medicine, Universidad Cientifica Del Sur, Lima 15054, Peru.
- School of Medicine, Universidad Nacional San Luis Gonzaga, Lima 15054, Peru.
- School of Medicine, Universidad Privada de Huancayo Franklin Roosevelt, Huancayo 12001, Peru.
- Department of Pediatrician and Neonatologist, Hospital Belen de Trujillo, Trujillo 12590, Peru.
Zitieren
APA
Fuentes-Mendoza, J. M., Concepción-Zavaleta, M. J., Dongo-Dueñas, L. G., Jara-Pianto, J. M. J., Sierra-Martel, J. A., Medina-Angulo, C. A., Virú-Flores, H. M., Mendoza-Godoy, J. J., Zavaleta-Gutiérrez, F. E., & Paz-Ibarra, J. (2026). Current and forthcoming pharmacotherapies for adolescent obesity: Evidence-based review. World Journal of Clinical Pediatrics, 15(3). https://doi.org/10.5409/wjcp.118730
Vancouver
Fuentes-Mendoza JM, Concepción-Zavaleta MJ, Dongo-Dueñas LG, Jara-Pianto JMJ, Sierra-Martel JA, Medina-Angulo CA, et al. Current and forthcoming pharmacotherapies for adolescent obesity: Evidence-based review. World Journal of Clinical Pediatrics. 2026;15(3). doi:10.5409/wjcp.118730
BibTeX
@article{FuentesMendoza2026,
author = {Fuentes-Mendoza, Jenyfer M and Concepción-Zavaleta, Marcio J and Dongo-Dueñas, Luisa Graciela and Jara-Pianto, Jose Mariano J and Sierra-Martel, Jhosmar Angel and Medina-Angulo, Claudio Aldahir and Virú-Flores, Horus Michael and Mendoza-Godoy, Jeny J and Zavaleta-Gutiérrez, Francisca E and Paz-Ibarra, José},
title = {Current and forthcoming pharmacotherapies for adolescent obesity: Evidence-based review},
journal = {World Journal of Clinical Pediatrics},
year = {2026},
volume = {15},
number = {3},
doi = {10.5409/wjcp.118730}
}
EUVIMED